We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-2.29%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.75B
AUM Growth
-$127M
Cap. Flow
+$174M
Cap. Flow %
6.34%
Top 10 Hldgs %
80.34%
Holding
44
New
6
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$113M
2
TNTR
Tintri, Inc. Common Stock
TNTR
+$38.2M
3
SNAP icon
Snap
SNAP
+$16.4M
4
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$12.8M
5
SENS icon
Senseonics Holdings Inc
SENS
+$11.3M

Top Sells

Rank Stock Value
1
GRPN icon
Groupon
GRPN
+$17.4M
2
HIVE
Aerohive Networks
HIVE
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.46%
2 Communication Services 1.93%
3 Technology 1.8%
4 Consumer Discretionary 1.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$1.44B 52.29%
10,275,113
– –
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$114M 4.14%
+325,771
New +$113M
AKAO
3
DELISTED
Achaogen Inc
AKAO
$113M 4.12%
5,215,128
– –
DERM
4
DELISTED
Dermira, Inc.
DERM
$102M 3.72%
3,506,649
– –
CBIO
5
Crescent Biopharma
CBIO
$598M
$95.8M 3.49%
85,841
– –
EPZM
6
DELISTED
Epizyme, Inc
EPZM
$94.5M 3.44%
6,260,851
– –
ARDX icon
7
Ardelyx
ARDX
$1.24B
$71.8M 2.61%
14,083,582
– –
RARX
8
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$65.5M 2.38%
3,493,636
– –
SENS icon
9
Senseonics Holdings Inc
SENS
$253M
$60.2M 2.19%
1,671,264
+356,000
+27% +$11.3M
ADAP
10
DELISTED
Adaptimmune Therapeutics
ADAP
$54M 1.96%
12,025,999
– –
CRSP icon
11
CRISPR Therapeutics
CRSP
$4.65B
$51.6M 1.88%
3,220,728
– –
CRCM
12
DELISTED
CARE.COM, INC.
CRCM
$49.2M 1.79%
3,260,989
– –
LXRX icon
13
Lexicon Pharmaceuticals
LXRX
$1.03B
$39.2M 1.43%
2,382,286
– –
GRPN icon
14
Groupon
GRPN
$1.05B
$38.5M 1.4%
501,894
-250,947
-33% -$17.4M
TNTR
15
DELISTED
Tintri, Inc. Common Stock
TNTR
$38.2M 1.39%
+5,253,358
New +$38.2M
AVEO
16
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$36.3M 1.32%
1,636,269
– –
CASC
17
DELISTED
Cascadian Therapeutics, Inc.
CASC
$33.7M 1.23%
9,064,575
– –
SBBP
18
DELISTED
Strongbridge Biopharma plc.
SBBP
$29.6M 1.08%
4,141,308
– –
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.92B
$29.5M 1.07%
4,808,483
– –
OBSV
20
DELISTED
ObsEva SA Ordinary Shares
OBSV
$28.5M 1.04%
3,336,563
– –
NVRO
21
DELISTED
NEVRO CORP.
NVRO
$26.8M 0.97%
359,678
– –
KA
22
DELISTED
Kineta, Inc. Common Stock
KA
$16.6M 0.61%
25,406
– –
SNAP icon
23
Snap
SNAP
$8.06B
$14.5M 0.53%
+813,802
New +$16.4M
SCMP
24
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$13.2M 0.48%
+1,258,507
New +$12.8M
ELGX
25
DELISTED
Endologix Inc
ELGX
$12.1M 0.44%
249,020
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q2 2017 Portfolio in Review

As of Q2 2017, NEA Management Company held 44 positions worth $2.75B, down 4.4% from $2.88B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

NEA Management Company deployed $174M of net new capital in Q2 2017, opening 6 new positions and adding to 1 existing holding. Its largest new stake was Mersana Therapeutics: 325,771 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Groupon, an estimated $17.4M trimmed.

  • NEA Management Company's largest Q2 2017 buy was Mersana Therapeutics: 325,771 shares worth $114M.
  • NEA Management Company added most to Senseonics Holdings Inc in Q2 2017, an estimated $11.3M increase.
  • NEA Management Company's biggest Q2 2017 reduction was Groupon, cutting an estimated $17.4M.
  • NEA Management Company's ten largest holdings make up 80% of its $2.75B portfolio in Q2 2017.
  • NEA Management Company opened 6 new positions and closed 0 in Q2 2017.
  • NEA Management Company's portfolio value fell 4.4% quarter-over-quarter to $2.75B.

Based on NEA Management Company's 13F filing for Q2 2017, filed 26 Jul 2017.